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LEE ET AL.: Early Results of Percutaneous Myocardial Revascularization with Three Dimensional Non-fluoroscopic
Electromechanical Mapping - A Novel Revascularization Therapy in Patients with End Stage Coronary Artery Disease.
Patients with end stage coronary artery disease who are not suitable candidate for conventional revascularization procedures
including percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting surgery (CABG)
can have disabling angina despite maximal medical treatment. Despite its convincing symptomatic benefit, transmyocardial
revascularization has limited role in these patients because of its significant perioperative morbidity and mortality.
Percutaneous route of direct laser myocardial revascularization (DMR) has emerged and initial results are encouraging.
We describe a novel way to perform DMR - with non-fluoroscopic electromechanical mapping. Between April to July
2000, we have performed DMR in six patients. Five patients had triple vessel disease and one had single vessel disease.
Five patients had prior PTCA and two had prior CABG. One patient had DMR to left arterior descending artery territory
and the other five had DMR to right coronary artery territory. The mean number of DMR channels was 23.3±2.9. There
was no acute complication. On three months follow up, three of four patients had angina class improved from class III to
II. One patient had remained in class III angina. The average number of additional nitrate tablets use decreased from 4 to
1.75 per week. Hence, DMR with non-fluoroscopic electromechanical mapping is a safe and feasible revascularization
option for patients with end stage coronary artery disease. (J HK Coll Cardiol 2000;8:179-184)
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Introduction
Coronary artery disease is the second leading
cause of death in Hong Kong. Revascularization by
either percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass grafting sugery
(CABG) constitutes an important part of the
management of these patients. However, a significant
proportion of patients have either diffuse coronary artery
disease, no adequate distal target vessels, chronic total
occlusion or blocked grafts, who are not amendable by
conventional PTCA or CABG. More importantly, they
may have disabling angina despite maximal antianginal
medication. It has been estimated that, in the United
States alone, there may be 200000 patients per year that
belong to this category.1
Transmyocardial revascularization (TMR)
designed to produce channels in the ischaemic
myocardium by carbon dioxide (CO2) laser has been
shown to improve angina class, prolong exercise
tolerance and, in some studies, enhance perfusion
in these patients with end stage coronary artery
disease.2-4 However, TMR requires general anaesthesia
and open thoracotomy and is associated with significant
perioperative morbidity and mortality. The development
of yttrium-aluminium-garnet (YAG) laser allows the
delivery of energy via optic fibers and hence the
emergence of direct myocardial revascularization
(DMR).5
While early results of DMR are encouraging, the
present technique is performed under conventional
fluoroscopic guidance which may be too crude for
precise positioning of the guiding and laser catheters.
Potential complications include damage to papillary
muscles and the mitral valve apparatus, repeated lasing
into the same area, myocardial perforation and
subsequent cardiac tamponade and ventricular
arrhythmia from catheter manipulation.
In this study, we describe the early results of a
non-fluoroscopic system to effect DMR.

Mapping and Laser System
The NOGA system (Biosense, Johnson and
Johnson) consists of an electrophysiological mapping
catheter with miniature magnetic field sensor at the tip,
a reference catheter with similar sensors at the tip, a
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location pad which generates an ultralow magnetic field
and a workstation which processes the information
obtained from the mapping catheter. The
electrophysiological counterpart (Biosense system) has
been described in our laboratory.6 The mapping catheter
(Noga Star, Biosense, Cordis) is introduced through an
8F femoral sheath and placed in the left ventricle as the
usual mapping catheter used in electrophysiology study.
The mapping catheter is then manipulated so as to make
a stable contact with the left ventricular endocardial
surface. The mapping catheter will then pick up the
electromagnetic signal and then its position relative to
the reference catheter will be determined. By moving
the mapping catheter tip to multiple left ventricular
endocardial sites, the workstation uses a triangular
algorithm to reconstruct the left ventricular anatomy.
A three dimensional mechanical map is constructed to
represent the local shortening function, with various
colour-coded for different degrees of motion. At the
same time, unipolar and bipolar endocardial potentials
are recorded by the electrode tip of the mapping catheter.
These will then be converted into a three dimensional
electrical map by displaying the voltage potentials on a
graded colour scale (Figure 1).
The ability of this new system to determine the
location and orientation of the catheter, to record local
electrogram from its tip and to reconstruct the three
dimensional geometry of the chamber with the
electrophysiological information colour-coded and
superimposed on the anatomy have been validated by
both in vitro and in vivo studies. 7 By using the
discrepancy between the unipolar voltage and linear
shortening, it has been suggested that this system could
differentiate between normal, ischaemic and hibernating
myocardium. 8-10 The target region is the ischaemic
myocardium which has normal voltage potential but
with impaired contraction (Figure 2).
An electromechanical mapping catheter
containing the location sensor and tip electrodes is
specifically designed to integrate with a laser fiber to
perform the left ventricular-mapped direct percutaneous
myocardial revascularization. With the real time
guidance of the catheter location, accurate creation of
multiple laser channels into the target zone of ischaemic
myocardium is possible. Each DMR channel is created
with a single 2-Joules pulse. Meanwhile, the exact
location of laser channels will be indicated on the map
and, hence, avoiding repeated lasing into the same site.
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Figure 1. Unipolar (left) and local shortening (right) maps of a patient with ischaemia. The colour code is indicated
on the right upper corner of each map. Notice the normal voltage potential and local shortening (blue to purple)
over the left ventricle and the physiological low voltage and local shortening (red) over the mitral annulus area.

Figure 2. Unipolar (left) and local shortening (right) maps (right anterior oblique view) in a patient with ischaemia
over right coronary artery territory. Notice the presence of electromechanical dissociation (red arrow) - i.e. normal
unipolar voltage (blue) with associated impaired local shortening (red).
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This article describes our early results of this novel
revascularization method in patients with end-stage
coronary artery disease.

Patients and Methods
Consecutive patients with end-stage coronary
artery disease satisfying the following inclusion criteria
were recruited.
1. Canadian Cardiologic Society (CCS) Angina Scale
class III or IV while receiving at least two antianginal
medications at the maximum tolerated doses.
2. All patients have severe coronary artery disease
which were not amendable to either PTCA or CABG
due to diffuse disease, complete occlusion, lack of
graftable vessels or any combination thereof.
3. Normal or only moderately impaired left ventricular
performance (ejection fraction >35%).
4. Stress induced myocardial perfusion defects on
thallium-201 scintigraphy.
5. Wall thickness in the DMR target region >8 mm as
determined by echocardiography. The "target
region" were defined as the region of stress induced
myocardial perfusion defects on thallium-201
scintigraphy which is not amendable to CABG or
PTCA.

at least 80 point recordings to profile the left ventricle,
and more sampling points at the target region. Then,
the laser catheter were used to create channels in the
target ischaemic region. Care was taken to space
channels at approximately equal distances of at least
1cm from each other, and a total of up to 25 applications
per myocardial region. Echocardiograms were
performed immediately and at 6-hour after the
procedure in order to exclude perforation of the left
ventricular wall and ensuing pericardial tamponade. All
patients were observed for 24 hours in the coronary care
unit and serial electrocardiograms and cardiac enzyme
levels were obtained. Clinical assessment including
quality of life questionnaire, echocardiography for
regional and global left ventricular function and
treadmill exercise were performed before, and at 3 after
the procedure.

Results
Between April to July 2000, we have performed
DMR in 6 patients. The baseline characteristics of this
cohort were shown in Table 1. Five patients had triple
vessel disease while one patient had chronic total
occlusion of the left anterior descending artery with
unsuccessful PTCA. Five patients (84%) had history of
prior PTCA and two (33%) had prior CABG. Those

Patients were excluded from DMR if they had
the following exclusion criteria:

Table 1. Baseline patient characteristics

1. Unprotected left main coronary artery disease >50%.
2. Unstable angina pectoris or a change in antianginal
medication within the last three weeks.
3. Myocardial infarction within the last three months.
4. Left ventricular thrombus.
5. Severe peripheral vascular disease that precluded
femoral artery access.
6. Aortic stenosis that prohibited catheter access to the
left ventricle.
7. Renal insufficiency with serum creatinine levels
>220 µmol/l.

Variables
Sex (Male : Female)
Age
Angina Class (CCS)III
Hypertension
Diabetes
Hypercholesterolaemia
Smoking
Stroke
Single vessel disease
Triple vessel disease
SVG disease
Prior PTCA
Prior CABG

All eligible patients underwent left
ventriculography performed in two orthrogonal views
using biplane imaging. Left ventricle electromechanical
mapping using the NOGA system were performed, with
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All patients (N=6)
5:1
68.5±4.9
6 (100%)
6 (100%)
2 (33%)
4 (66%)
3 (50%)
1 (16%)
1 (16%)
5 (84%)
2 (33%)
5 (84%)
2 (33%)

CABG: coronary artery bypass grafting; CCS: Canadian
Cardiovascular Society; PTCA: percutaneous transluminal coronary
angioplasty; SVG: saphenou vein graft
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two patients with prior CABG had degenerated vein
graft disease which deemed not revascularizable by
PTCA, and the patient declined a repeated CABG.
One patient had DMR to left arterior descending
artery territory while the remaining 5 patients had DMR
to right coronary artery territory (Figure 3). The mean
number of DMR channels created was 23.3±2.9.
Procedure time ranged from 95 to 160 minutes, with a
mean of 124±26 minutes. Mean fluoroscopy time was
16±10 minutes. There was no acute complication
including perforation of ventricle, cardiac tamponade,
sustained ventricular arrhythmia and myocardial
ischaemia. All patients were discharged on the next day
following the procedure.
Four patients had three months follow up. Three
patients (75%) had improvement of their angina class
from class III to II while 1 patient had no significant
improvement (still in CCS class III). The average
number of additional oral nitrate taken decreased from
4 per week to 1.75 per week.

Discussion
Most patients with coronary artery disease have
their angina symptoms well controlled with a
combination of antianginal medications and
revascularization procedure, either by PTCA or CABG.
However, patients with end stage coronary artery disease
may have disabling angina symptom despite maximal
medical treatment. More importantly, they are not
candidates for conventional revascularization because
of diffuse disease, small distal vessels, chronic total
occlusion without graftable distal vessels and history
of multiple bypass surgeries. The need for an alternate
revascularization is clear.
TMR is proven to improve angina class, increase
exercise tolerance and improve quality of life in patients
with end stage coronary artery disease.2-4 However, there
is so far no convincing improvement in myocardial
perfusion as documented by nuclear scintingraphy. In
a randomized study, Schofield et al reported a
nonsignificant trend of increased mortality in TMR
treated group.11
The underlying mechanism of TMR is still
unknown. Long term patency of the laser channels, as
was initially suggested, was refuted.12 Sympathetic
dennervation was also suggested to be contributory.13
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More recently, promoted angiogensis in the scar tissue
is believed to be the chief mechanism in improving the
myocardial perfusion and hence clinical response.14,15
The limitation of TMR is the relatively high
perioperative mortality, in the range of 5-9%. The
requirement of general anaesthesia and thoracotomy
also hinder its widespread use. It is criticized that the
different studies reporting the clinical results of TMR
lacked rigorous solid outcome endpoints to enable
objective assessment of the clinical effect of this
treatment modality. Meanwhile, possible placebo effect
on the treatment group can not be neglected. Moreover,
the disparity between clinical improvement and
objective assessment of myocardium perfusion by
nuclear scan cannot be explained. Last but not the least,
the underlying mechanism for the subjective clinical
improvement still remains unknown.
The initial results of DMR are encouraging.
Similar to TMR, it is able to improve angina class,
increase exercise time and reduce additional nitrate
use.16-18 More importantly, it is associated with much
lower perioperative morbidity and mortality. The
NOGA system can produce three-dimensional real time
left ventricular electromechanical map. This may help
to identify the target ischaemic region as opposed to
the normal or infarcted regions. This may facilitate the
target of the laser catheter to the appropriate region. It
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Figure 3. Posteroanterior view of an unipolar map
in a patient who had PMR to the inferior wall.
Each brown dots denotes a laser channel.
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may also help to avoid creating laser channels in mitral
annulus area. Repeated lasing in the same channels can
also be prevented.
Patients with disabling angina (CCS class ≥3),
small, diffusely diseased and nongraftable distal vessels,
chronic total occlusion or blocked grafts are suitable
candidates for DMR. DMR is able to reduce angina
symptom and improve exercise tolerance. As shown by
our cohort, DMR performed with LV electromechanical
mapping is a feasible alternative. It is associated with
high procedural success and low complication rate.
More importantly, it reduces radiation exposure to
medical staff as compared with DMR performed with
conventional fluoroscopy.

Conclusion
DMR with non-fluoroscopic electromechanical
mapping is a safe and feasible therapy for patients with
end-stage coronary artery disease. Moreover, this
revascularization therapy is associated with
symptomatic improvement in these patients who have
disabling angina.
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